INTRODUCTION
Trichosporon species have become increasingly recognized as opportunistic pathogens capable of causing disseminated infections. Cutaneous lesions are fairly common and may serve as a diagnostic clue to invasive Trichosporon infection. We report a case of disseminated trichosporonosis in an immunocompromised patient who presented with purpuric and cream-colored plaques.
CASE REPORT
A 67-year-old man with insulin-dependent diabetes mellitus and chronic kidney disease was admitted to the hospital for perforated ischemic colitis requiring exploratory laparotomy and partial colectomy. He was taking tacrolimus and methylprednisolone for immunosuppression for a cardiac transplantation 8 years ago. His hospital course was complicated by ventilator-dependent respiratory failure, and he was given broad-spectrum antimicrobials, including meropenem, vancomycin, and caspofungin, for culture-negative fevers. Approximately 4 weeks into his hospitalization, he had creamcolored plaques with surrounding stellate purpura and necrosis on the right medial thigh and scrotum and multiple blue-black bullous plaques on the right foot (Fig 1) . Laboratory testing found a white blood cell count of 18,600/L (reference range 4,000e11,000/L), hemoglobin of 8.3 g/dL (reference range, 13.5e17.5 g/dL), and serum creatinine of 2.38 mg/dL (reference range, 0.64e1.27 mg/dL).
A bedside potassium hydroxide preparation performed from the right thigh lesion found fungal elements (Fig 2, A) , and immediate frozen section, standard skin biopsy, and tissue cultures were also performed. The skin biopsy found acute necrotizing inflammation, hemorrhage, and deep fungal infection in the skin and subcutis, with pleomorphic yeast and hyphae forms highlighted on Periodic AcideSchiff and Grocott stains (Fig 2, B) . Trichosporon asahii was isolated from skin tissue culture and subsequently from respiratory and blood cultures. Fungal culture plates found characteristic morphology of the yeast (Fig 2, C ) , which resembled the cream-colored plaques on the patient's skin.
The patient's antifungal therapy was switched to voriconazole and amphotericin, and his immunosuppressive medications were stopped. Despite these measures, his condition continued to deteriorate, and he died a few days after diagnosis of the disseminated infection.
DISCUSSION
Trichosporon species are basidiomycetous yeasts that are ubiquitous in the environment but can colonize the gastrointestinal and urinary tracts, respiratory airways, and skin. 1 Although Trichosporon is most commonly associated with white piedra, a benign superficial infection of the hair, it has become increasingly recognized as an opportunistic pathogen capable of causing invasive and fatal infection. 2 Trichosporon is the second most common cause, after Candida, of disseminated yeast infection in patients with hematologic malignancies. 1 Of the 50 Trichosporon species classified to date, T asahii is the most common cause of invasive infection, followed by Trichosporon mucoides and Trichosporon asteroides. Invasive trichosporonosis generally affects immunocompromised persons, particularly those with hematologic malignancies or history of organ transplantation. [1] [2] [3] [4] It has also been reported in persons with AIDS and critically ill patients without other underlying immunosuppression. 1, 5, 6 While exogenous inoculation may cause infection, such as in catheter-associated cases, it has been theorized that mucosal, including gut, colonization with Trichosporon and subsequent translocation may lead to deep-seated infection.
1 Fungemia and fever are the most common findings in disseminated trichosporonosis. Approximately 30% of patients subsequently have cutaneous lesions, which present as red or purpuric papules, vesicles, and nodules, often with necrosis or ulceration. 6 Organs such as the lung, liver, heart, brain, and urinary tract may also be infected.
Early diagnosis of invasive trichosporonosis is critical and can be made using tissue histology and culture. Although limited data exist on the antifungal susceptibilities of Trichosporon species, triazoles, including voriconazole, appear to have the greatest activity and are recommended as first-line therapy. 3, 4, 7 However, breakthrough Trichosporon infections have been noted in patients even after the administration of triazoles, 1, [7] [8] [9] and multiple Trichosporon species can produce triazole-resistant biofilms. 10 In addition, increasing evidence suggests that amphotericin and echinocandins have little to no efficacy against Trichosporon. 1, 8 Despite antifungal therapy, invasive trichosporonosis carries a mortality rate of 50% to 80%. 
